Top Markets
#1 ADO Protocol ADO Protocol +337.07%
#2 GoPlus Security GoPlus Security +52.45%
#3 Starpower Starpower +36.27%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.77%
#5 GAIB AID GAIB AID +24.67%
#6 The Black Bull The Black Bull +20.07%
#7 Nockchain Nockchain +18.00%
#8 Fake World Assets Fake World Assets +17.14%
#9 DMT-NAT DMT-NAT +14.82%
#10 Casper Network Casper Network +11.97%
Coin of the day
ADO Protocol ADO Protocol
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Rangering i aksjer #33301
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Aksjekurs
$0.4264
Sist synkronisert: 2022-09-14
Markedsverdi
$7.93M
Endring (1 dag)
-16.44%
Endring (1 år)
0.00%
Land
US
Handel Caladrius Biosciences, Inc. (CLBS)

Kategori

Healthcare
P/B-forhold for Caladrius Biosciences, Inc. (CLBS)
P/B-forhold per 2026 TTM: 0
Ifølge Caladrius Biosciences, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Caladrius Biosciences, Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE